GU Cancers 2022 | TMB as a predictive biomarker for ICI versus taxane chemotherapy benefit in mCRPC

Nicolas Sayegh, MD, University of Utah, Salt Lake City, UT, & Ryon Graf, PhD, Foundation Medicine, San Diego, CA, discuss the findings of a real-world biomarker study evaluating tumor mutational burden (TMB) as a predictive biomarker for immune checkpoint inhibitor (ICI) versus taxane chemotherapy benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). Results suggest immune checkpoint inhibitors may be a viable alternative to taxane chemotherapy for patients with mCRPC with TMB = 10. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.